I

Innate Pharma SA

IPHA

2.19000
USD
0.06
(2.82%)
مغلق
حجم التداول
2,152
الربح لكل سهم
0
العائد الربحي
0
P/E
-4
حجم السوق
155,425,501
أصول ذات صلة
A
ACAD
-0.020
(-0.11%)
19.000 USD
A
ACHV
-0.22000
(-4.40%)
4.78000 USD
A
ALT
-0.27000
(-4.24%)
6.10000 USD
C
CYTK
-1.150
(-1.95%)
57.910 USD
I
INO
-0.670
(-6.28%)
10.000 USD
M
MRNS
0.00000
(0.00%)
1.40000 USD
S
SNDL
-0.07000
(-3.08%)
2.20000 USD
T
TRVN
-0.00830
(-3.91%)
0.20390 USD
الأخبار المقالات

العنوان: Innate Pharma SA

القطاع: Healthcare
الصناعة: Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.